Investigation of the role of cysteinyl leukotriene (CysLT) receptors in Uveal Melanoma
Kaelin Smith
Kaelin Smith is a research assistant joining the Ocular Pharmacology and Genetics Group at University College Dublin. He will join a Breakthrough Cancer Research-funded project that aims to investigate the role of cysteinyl leukotriene (CysLT) receptors in Uveal Melanoma and whether blocking these receptors with drugs can alter different cancer hallmarks.
RESEARCH FINDINGS
Publications:
Slater K, Bosch R, Smith KF, Jahangir CA, Garcia-Mulero S, Rahman A, O’Connell F, Piulats JM, O’Neill V, Horgan N, Coupland SE, O’Sullivan J, Gallagher WM, Villanueva A, Kennedy BN. 1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model. Front Med (Lausanne). 2023 Jan 9;9:1036322. PMID: 36698840; PMCID: PMC9868667. doi: 10.3389/fmed.2022.1036322.
Back
Start year
2020
End year
2021
Principal Investigator
Prof. Breandan Kennedy
Researcher
Kaelin Smith
Institution
University College Dublin
Grant funding
Breakthrough Project Grant
Linked Breakthrough Research Priorities
Increase research investment into poor prognosis cancers and currently incurable cancers prioritising lung, oesophageal, ovarian, pancreatic, brain, liver and stomach cancers.
Fund the discovery and development of new therapeutics, surgical approaches and technologies, including biological and immune approaches, to improve cancer treatment.
Fund research which aims to improve the effectiveness or specificity of current cancer therapies including investing in biomarkers discovery, nutrition and therapeutic delivery.
Contact